By Clare Lamberth, Larimedical Business Development Manager, The Australian Dermal & Laser Institute (TADLI)
When clinic owners first reach out to me, the conversation rarely starts with products. It starts with frustration.
Most practitioners are not lacking tools. What they are lacking is predictability – particularly when it comes to melasma. They are dealing with clients who have tried everything, only for pigment to return aggressively at the slightest trigger.
The cycle is demoralising for everyone involved: temporary brightening, rapid rebound, eroded client trust, and a therapist left feeling like they are fighting a losing battle. The question is – why does this keep happening?
We’re Treating the Wrong Thing
Therapists across Australia are exceptionally well-trained, but the gap often lies in treating melasma purely as a pigment problem rather than what it actually is: a chronic inflammatory and vascular disorder.
Most practitioners focus on the pigment pathway – melanogenesis and tyrosinase inhibition. But the picture is far more complex. A disrupted basement membrane allows melanocytes and melanin to drop into the dermis. Vascular endothelial growth factor feeds melanocyte hyperactivity. Chronic low-grade inflammation keeps melanocytes in a perpetual state of defence. When we treat only what we can see, we miss what is driving it. The shift that changes everything is moving from “how do we strip or inhibit this pigment?” to “how do we repair the environment and restore tissue homeostasis?”
The Most Common Mistake
The single most common error I see is over-treating with excessive aggression – heavy chemical trauma, over-zealous heat, or pushing skin barrier boundaries too quickly. High-trauma modalities may deliver temporary shedding of superficial pigment, but they exacerbate basement membrane degradation and trigger post-inflammatory hyperpigmentation. The result is the classic melasma boomerang. Short-term brightening, followed by aggressive rebound. It is not a failure of the therapist – it is a failure of the approach.
What Biomimetic Actually Means
When I explain biomimetic technology to a practitioner for the first time, I describe it simply: it speaks to the skin rather than at it. Traditional peels for pigmentation rely on brute force – acids that dramatically lower pH to destroy cellular bonds and force epidermal shedding. Biomimetic formulations work differently. They mimic the natural physiological processes of the skin, integrating seamlessly into cellular pathways and signalling the skin to regulate, repair and renew from within.
It is the difference between breaking down a door to get inside versus using the exact key that unlocks it. You achieve target-specific results without the collateral damage. This is precisely the philosophy behind Larimedical’s biomimetic peel range – and why it has become one of the most clinically compelling tools available for treating melasma and stubborn pigmentation without the risks associated with conventional peeling agents.
What Clinics Are Actually Seeing
The primary shift clinics are reporting is something that has historically been elusive in melasma treatment: stability. With conventional peels, clinics face high downtime, significant peeling and a real risk of PIH or rebound – particularly in warmer months. With a biomimetic peel protocol, practitioners are achieving significant clearance of both epidermal and stubborn dermal pigment, reduced vascular flushing within lesion sites and a restored skin barrier – safely, year-round.
The most dramatic results are being seen in higher Fitzpatrick presentations – types III through VI – and in clients with vascular or recalcitrant melasma. Historically, treating darker skin tones for pigmentation carried substantial PIH risk. The biomimetic approach removes that risk because it does not rely on inflammatory destruction to achieve active penetration.
For the Therapist Still Hesitating
I understand the hesitation completely. For decades, our industry conditioned us to believe that no visible erythema, no heavy desquamation, no result. We tied clinical efficacy to visible trauma.
Advanced skin science has moved well beyond that. We now understand that chronic inflammation accelerates ageing, breaks down the dermal matrix and triggers pigment relapse. Moving away from aggressive peeling is not a step back – it is a step forward into modern cellular biology. When you shift to a biomimetic methodology, you are not sacrificing results. You are achieving superior, longer-lasting outcomes with significantly lower risk and higher client compliance.
The skin does not need to be fought. It needs to be understood.
Clare Lamberth is the Larimedical Business Development Manager at The Australian Dermal & Laser Institute (TADLI) and a 2026 ABIA finalist for Best Sales and Business Development Representative. To find out more about the Larimedical biomimetic peel range, visit www.tadli.com.au
.
